Article
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
British journal of clinical pharmacology - 1 Nov 2015
Bachmann Hagen Sjard, Meier Werner, du Bois Andreas, Kimmig Rainer, Kuhlmann Jan Dominik, Siffert Winfried, Sehouli Jalid, Wollschlaeger Kerstin, Huober Jens, Hillemanns Peter, Burges Alexander, Schmalfeldt Barbara, Aminossadati Behnaz, Wimberger Pauline
Abstract excerpt
AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced ovarian cancer. This study was performed as a genetic subgroup analysis of the AGO-OVAR-15 trial, and investigated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.